Martin Gelbard

UCLA School of Medicine

Dr. Gelbard Bio


Dr. Martin Gelbard is widely recognized for his work in the treatment of Peyronie’s Disease - as a physician, reconstructive surgeon, and as a research investigator in both the laboratory and clinic. His original laboratory work in 1982 was the first to identify clostridial collagenase as a potential non-surgical remedy for Peyronie’s Disease. His subsequent clinical experience with this agent has ranged from conducting the first clinical trials with what eventually became Xiaflex® in 1985 to participating as a principal investigator in the multi institutional clinical trials which led to U.S. FDA approval in 2013. He authored the first scientific paper advocating the incision of Peyronie’s plaques rather than their excision, a practice that has since been widely incorporated into conventional surgical practice. A respected reconstructive surgeon, he has the distinction of having the world’s largest experience with collagenase clostridium histolyticum (Xiaflex®) in the treatment of Peyronie’s Disease. He is a graduate of Stanford University and the University of California, Davis School of Medicine. His postgraduate residency training involved 2 years in general surgery, then 4 years in the Urology program at UCLA, where he remains as clinical assistant professor.

Presentation(s):

Send Email for Martin Gelbard